Abstract 4565
Background
The residual disease (RD) after debulking surgery is one of the strongest prognostic factors in ovarian cancer (OC) patients. Despite surgical efforts, most patients do not achieve "optimal" cytoreduction (R0) even in high-volume centres. The interplay between cancer-promoted angiogenesis and host immune-system could foster cancer dissemination, reducing the likelihood of surgical eradication. The aim of this study was to assess whether the presence of germline polymorphisms in genes involved in angiogenesis and immunity pathways was predictive of R0.
Methods
A cohort of 230 patients with stage III-IV, high grade epithelial OC treated with debulking surgery and platinum-based therapy without bevacizumab, was retrospectively enrolled. A panel of 192 single nucleotide polymorphisms (SNPs) in 34 angiogenesis and immune system-related genes was analyzed with Illumina GoldenGate Genotyping Assay. Log-additive, dominant and recessive genetic models were evaluated using a multivariate logistic regression adjusted for type of surgery (i.e. primary or interval). False discovery rate (FDR) test<0.2 was used for multiple testing data correction.
Results
Thirteen SNPs were significantly associated with RD. Among them, MMP3-rs569444, TLR3-rs5743303 and VEGFA-rs2146323 passed the FDR filter. Patients carrying the variant alleles of MMP3-rs569444 (OR = 2.52, 95%CI 1.42-4.47, p = 0.0326) and VEGFA-rs2146323 (OR = 1.83, 95%CI 1.21-2.75, p = 0.0375) showed an increased risk of RD. Conversely, TLR3-rs5743303 carriers were more likely to achieve R0 (OR = 0.43, 95%CI 0.27-0.7, p = 0.0004).
Conclusions
Angiogenesis and the immune-system competence are key players in OC growth and could influence the burden of RD. In our cohort, individual polymorphisms on angiogenesis (VEGFA), extracellular matrix degradation (MMP3) and innate immunity activation (TLR3) pathways were independent predictive factors of RD. These markers, whether validated, might underline the role of host genetics factors in predicting R0. Moreover, if VEGFA-rs2146323 variant carriers could benefit the most from bevacizumab appears as an intriguing question.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Toffoli Giuseppe.
Funding
Has not received any funding.
Disclosure
F. Puglisi: Honoraria (self), Advisory / Consultancy: Amgen; Advisory / Consultancy: Celgene; Advisory / Consultancy: Eisai; Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self): Pierre Fabre; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Takeda; Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract